Feed MRNA
MR

Moderna MRNA · NASDAQ

$226.30 +4.65% (+$10.05)

Market cap
$89.8B
Enterprise value
$89.4B
P/E
-
Forward P/E
-
PEG
-
P/S
40.3x
P/FCF
-
EV/EBITDA
-
ROIC
-40.0%
Bruto marža
-12.6%
Neto marža
-141.4%
Dividend yield
-
Payout ratio
-
Neto dolg/EBITDA
-
Beta
0.90
Free float
93.2%

O podjetju

Moderna (MRNA) is a biopharmaceutical company specializing in the development of innovative drugs and vaccines. Their primary focus is on mRNA technology, which enables the creation of therapeutic and preventive products with high efficacy and safety. Moderna gained significant attention for its development of a COVID-19 vaccine, which has been approved and successfully deployed worldwide. Moderna stock is suitable for investors interested in the biotechnology sector and seeking opportunities in the field of therapeutic innovations and vaccines. Add Moderna stock to your watchlist on Bulios and be the first to receive updates on new developments, medical breakthroughs, and vaccines from this prominent company.

Sector

Healthcare

Industry

Biotechnology

CEO

Stéphane Bancel

Employees

4,700

Headquarters

Cambridge

Vrednotenje

Je današnja cena primerna?

Rast in ocene

Ali podjetje raste in kaj sledi?

Donosnost in kakovost

Koliko prihodkov ostane in kako dobro podjetje uporablja kapital?

Finančno zdravje

Ali zmore svoj dolg?

Kapital in dividende

Kaj podjetje počne z zasluženim denarjem?

Analitiki

Kaj menijo strokovnjaki in ali se to spreminja?

Lastniki in insajderji

Kdo ima delnice in kaj počne vodstvo?

Segmenti

Kateri del podjetja raste?

Primerjava s konkurenco

Kako se primerja s podobnimi podjetji?

Cena in tveganje

Kako se delnica obnaša?

Izkazi

Vse številke

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.